Sutro Biopharma (STRO) News Today $2.67 -0.03 (-1.11%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Brokers Set Expectations for Sutro Biopharma FY2024 EarningsSutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Investment analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Sutro Biopharma in a research report issued on Monday, November 18th. HC Wainwright analyst A. Fein now anticipates that the company will eNovember 20 at 6:23 AM | marketbeat.comAnalysts Set Expectations for Sutro Biopharma Q2 EarningsSutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of Sutro Biopharma in a research note issued on Monday, November 18th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.87) per sharNovember 19 at 6:36 AM | marketbeat.comAnalysts Issue Forecasts for Sutro Biopharma FY2024 EarningsNovember 19 at 1:35 AM | americanbankingnews.comSutro Biopharma’s Innovative ADC Technology and Strategic Partnerships Signal Strong Growth PotentialNovember 18 at 7:04 PM | markets.businessinsider.comSutro Biopharma's (STRO) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Sutro Biopharma in a research note on Monday.November 18 at 8:11 AM | marketbeat.comSutro Biopharma FY2024 EPS Forecast Increased by WedbushSutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Analysts at Wedbush boosted their FY2024 earnings per share estimates for Sutro Biopharma in a research report issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($2.93) per shaNovember 18 at 1:30 AM | marketbeat.comSutro Biopharma, Inc.: Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 15, 2024 | finanznachrichten.deSutro Biopharma: Hold Rating Amidst Uncertain Catalysts and Funding ConcernsNovember 15, 2024 | markets.businessinsider.comSutro Biopharma (STRO) Receives a Buy from Truist FinancialNovember 15, 2024 | markets.businessinsider.comSutro Biopharma’s Promising Market Expansion and Financial Stability Justify ‘Buy’ RatingNovember 15, 2024 | markets.businessinsider.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 17.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,519,341 shares of the company's stock after selling 329,410 shares during the quarter.November 14, 2024 | marketbeat.comSutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 13, 2024 | globenewswire.comSutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceNovember 4, 2024 | globenewswire.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Buy" from BrokeragesShares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have earned a consensus rating of "Buy" from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month price target amongNovember 3, 2024 | marketbeat.comSutro Biopharma initiates REFRaME-P1 trial of luvelta in AMLNovember 2, 2024 | markets.businessinsider.comSutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AMLNovember 1, 2024 | globenewswire.comSutro Biopharma (NASDAQ:STRO) Stock Quotes, Forecast and News SummaryOctober 29, 2024 | benzinga.comSutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years agoOctober 21, 2024 | finance.yahoo.comSutro Elementary parents decry 'chaos' at SF Unified over school closuresOctober 18, 2024 | msn.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC lessened its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 91.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,463 shares of the company's stocOctober 17, 2024 | marketbeat.comAQR Capital Management LLC Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)AQR Capital Management LLC lifted its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 691.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 283,516 shares of the company's stock after acquiring an additional 247,694 shares duringOctober 13, 2024 | marketbeat.comSutro Biopharma: Poised to Become an ADC Powerhouse with Innovative XpressCF(+) PlatformOctober 12, 2024 | markets.businessinsider.comSutro Biopharma’s Promising ADC Innovations and Strategic Collaborations Justify a Buy RatingOctober 12, 2024 | markets.businessinsider.comTruist Financial Issues a Buy Rating on Sutro Biopharma (STRO)October 11, 2024 | markets.businessinsider.comSutro Biopharma (STRO) Gets a Buy from WedbushOctober 11, 2024 | markets.businessinsider.comSutro Biopharma's (STRO) "Overweight" Rating Reaffirmed at Piper SandlerPiper Sandler reissued an "overweight" rating and set a $11.00 price objective on shares of Sutro Biopharma in a research report on Friday.October 11, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Dimensional Fund Advisors LPDimensional Fund Advisors LP trimmed its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 17.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,085,281 shares of the compOctober 11, 2024 | marketbeat.comSutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research ForumOctober 10, 2024 | globenewswire.comMillennium Management LLC Trims Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)Millennium Management LLC lessened its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 7.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,361,893 shares of the company'sOctober 8, 2024 | marketbeat.comRenaissance Technologies LLC Increases Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)Renaissance Technologies LLC raised its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 48.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 719,497 shares of the company's stock after purchasing an additional 2October 3, 2024 | marketbeat.comPoint72 Asset Management L.P. Increases Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)Point72 Asset Management L.P. increased its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 1,606.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,447,634 shares of the company's stOctober 1, 2024 | marketbeat.comMotorcyclist killed in crash at Sutro and East 6th streets Wednesday eveningSeptember 27, 2024 | msn.comSutro Biopharma, Inc.: Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 21, 2024 | finanznachrichten.deSutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 20, 2024 | globenewswire.comBuy Rating for Sutro Biopharma Backed by Promising Luvelta Phase 1b Trial ResultsSeptember 17, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)September 16, 2024 | markets.businessinsider.comAnalyst Expectations For Sutro Biopharma's FutureSeptember 16, 2024 | benzinga.comSutro Biopharma (NASDAQ:STRO) Earns Market Outperform Rating from JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $17.00 price target on shares of Sutro Biopharma in a research report on Monday.September 16, 2024 | marketbeat.comStrong Buy Rating for Sutro Biopharma on Promising Clinical Data and Strategic Market PositioningSeptember 16, 2024 | markets.businessinsider.comSutro Biopharma, Inc.: Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024September 14, 2024 | finanznachrichten.deSutro Announces Updated Data From Phase 1b Study Of Luvelta Combination In Epithelial Ovarian CancerSeptember 14, 2024 | markets.businessinsider.comSutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024September 14, 2024 | globenewswire.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Buy" from BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight research firms that are currently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy rating. The average 1 year price objective among analysSeptember 14, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Purchased by Acadian Asset Management LLCAcadian Asset Management LLC grew its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 30.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,574,958 shares of the comSeptember 12, 2024 | marketbeat.comSutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024September 11, 2024 | globenewswire.comPanagora Asset Management Inc. Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)Panagora Asset Management Inc. grew its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 15.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 907,503 shares of the company's stock after purchasingAugust 31, 2024 | marketbeat.comSutro Biopharma’s Promising Oncology Prospects and Solid Financials Merit a Buy RatingAugust 23, 2024 | markets.businessinsider.comSutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung CancerAugust 22, 2024 | globenewswire.comSutro Biopharma maintained its Buy rating from TD CowenAugust 16, 2024 | uk.investing.comSutro Biopharma (NASDAQ:STRO) PT Lowered to $15.00 at Truist FinancialTruist Financial cut their price target on shares of Sutro Biopharma from $18.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday.August 16, 2024 | marketbeat.com Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO STRO Media Mentions By Week STRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STRO News Sentiment▼0.860.45▲Average Medical News Sentiment STRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STRO Articles This Week▼202▲STRO Articles Average Week Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nuvation Bio News 89bio News Tyra Biosciences News Rapport Therapeutics News Relay Therapeutics News Evolus News Pliant Therapeutics News Cronos Group News Prothena News Replimune Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STRO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
